Clinical Trials Details

PrE1702: Prospective Non-Interventional Study Comparing Standard of Care Osimertinib +/- Chemotherapy) for EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patients

Summary

The goal of the study is to collect data on patients treated outside of a clinical trial (in routine clinical practice) with standard of care osimertinib with or without chemotherapy in Epidermal Growth Factor Receptor (EGFR)-mutant Non-Small Cell Lung Cancer (NSCLC) to better understand the safety and effectiveness of these standard of care regimens.

More information